07 November 2014, Manchester – This year’s unique BioInfect conference organised by Bionow, a not for profit membership organisation for the biomedical / life-sciences industry, was a major success. Exploring the global anti-microbial agenda, BioInfect looked at new innovations currently in progress to tackle the increasing problem. The one day conference, which addressed the critical issues relating to the development of new anti-infectives and the endemic problem of resistance, took place at the Alderley Park Conference Centre, Cheshire on the 4th November 2014.
The conference brought together scientists, policy makers and government officials who convened to set the anti-microbial agenda. There were three main sessions presented at the conference entitled: “Progress: National and International Perspectives”, “Animal Health – the issues” and “Commercial Models.” In addition, there was a company technology showcase presenting leading innovation and development in this area.
Technology showcased at BioInfect included the latest innovations from companies from the north of the UK. These included the development of a wide range of early stage, proprietary therapeutics moving away from a broad spectrum approach to more focused methodologies more akin to the targeted approach now being taken with cancer. In addition, there was particular focus on the development of innovative therapies employing cutting-edge nanopolymer drug delivery technology, and also taking biologic and vaccine approaches to developing treatments to meet the high unmet medical need.
BioInfect explored other research into technological tools for health workers to diagnose, manage, monitor and track emerging infections and drug resistance as well as discovery and development of novel drugs to treat life threatening fungal diseases. Fungal infection typically affects the immune-compromised patient where mortality rates are often very high. This patient population is increasing year by year due to increased cases of cancer, organ transplants and the use of potent medicines that affect the immune system.
Dr Geoff Davison, Chief Executive Officer of Bionow, commented: “We are very pleased with the attendance, engagement and feedback received and that the key areas which can move this agenda forward were discussed. BioInfect brings together professionals from the life sciences industry, universities, NHS, government and policy making bodies and allows them to explore the areas which can truly address this problem for mankind. In order to tackle growing levels of antimicrobial resistance, we need to address this global problem in a truly coordinated way by open and coordinated discussion and planning to ensure that we have a health care system that can sustainably control and treat infections.”
BioInfect 2014, was hosted by Bionow and Redx Pharma, supported by AstraZeneca and was sponsored by HGF Ltd, Boyds and Shore Capital.
BioInfect 2015 will go ahead on Wednesday 4th November 2015 at the Alderley Park Conference Centre, Cheshire. For more information please contact Helen Williams on 07714 168020 or at helen.williams@bionow.co.uk.
Ends
About Bionow
Bionow is a not for profit membership organisation for the biomedical / life-sciences industry in the North of England and supports business growth, competitiveness and innovation. Our membership base includes start-ups and early stage firms as well as established growth-oriented companies. Bionow's membership offering focuses upon the specific needs of firms at their different stages of development, including dedicated business support programmes, shared procurement schemes with significant cost savings, exclusive insurance benefits, recruitment and training services, local and national events and access to a vibrant network of businesses. For more information, visit www.bionow.co.uk
For further press information please contact: Vanessa Wright, The Scott Partnership, 1, Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom Tel: + 44 1477 539539 Fax: +44 1477 539539 Email to: bionow@scottpr.com
Helen Williams, Events and Marketing Manager, Bionow: + 44 7714 168020
Email to: helen.williams@bionow.co.uk
Help employers find you! Check out all the jobs and post your resume.
Technology showcased at BioInfect included the latest innovations from companies from the north of the UK. These included the development of a wide range of early stage, proprietary therapeutics moving away from a broad spectrum approach to more focused methodologies more akin to the targeted approach now being taken with cancer. In addition, there was particular focus on the development of innovative therapies employing cutting-edge nanopolymer drug delivery technology, and also taking biologic and vaccine approaches to developing treatments to meet the high unmet medical need.
BioInfect explored other research into technological tools for health workers to diagnose, manage, monitor and track emerging infections and drug resistance as well as discovery and development of novel drugs to treat life threatening fungal diseases. Fungal infection typically affects the immune-compromised patient where mortality rates are often very high. This patient population is increasing year by year due to increased cases of cancer, organ transplants and the use of potent medicines that affect the immune system.
Dr Geoff Davison, Chief Executive Officer of Bionow, commented: “We are very pleased with the attendance, engagement and feedback received and that the key areas which can move this agenda forward were discussed. BioInfect brings together professionals from the life sciences industry, universities, NHS, government and policy making bodies and allows them to explore the areas which can truly address this problem for mankind. In order to tackle growing levels of antimicrobial resistance, we need to address this global problem in a truly coordinated way by open and coordinated discussion and planning to ensure that we have a health care system that can sustainably control and treat infections.”
BioInfect 2014, was hosted by Bionow and Redx Pharma, supported by AstraZeneca and was sponsored by HGF Ltd, Boyds and Shore Capital.
BioInfect 2015 will go ahead on Wednesday 4th November 2015 at the Alderley Park Conference Centre, Cheshire. For more information please contact Helen Williams on 07714 168020 or at helen.williams@bionow.co.uk.
Ends
About Bionow
Bionow is a not for profit membership organisation for the biomedical / life-sciences industry in the North of England and supports business growth, competitiveness and innovation. Our membership base includes start-ups and early stage firms as well as established growth-oriented companies. Bionow's membership offering focuses upon the specific needs of firms at their different stages of development, including dedicated business support programmes, shared procurement schemes with significant cost savings, exclusive insurance benefits, recruitment and training services, local and national events and access to a vibrant network of businesses. For more information, visit www.bionow.co.uk
For further press information please contact: Vanessa Wright, The Scott Partnership, 1, Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom Tel: + 44 1477 539539 Fax: +44 1477 539539 Email to: bionow@scottpr.com
Helen Williams, Events and Marketing Manager, Bionow: + 44 7714 168020
Email to: helen.williams@bionow.co.uk
Help employers find you! Check out all the jobs and post your resume.
